Search

Displaying results 9641 - 9650 of 10000 in total
  1. Drug

    NTLA-2001

    go.drugbank.com/drugs/DB18525
    Investigational

    NTLA-2001 is a clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9.

  2. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    It is under investigation for the treatment of ovarian cancer.

  3. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  4. Drug

    3,3'-diindolylmethane

    go.drugbank.com/drugs/DB11875
    Investigational

    Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others.

  5. Drug

    Exebacase

    go.drugbank.com/drugs/DB16161
    Investigational

    Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).

  6. Drug

    Fenpyroximate

    go.drugbank.com/drugs/DB16164
    Investigational

    Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

    Synonyms: Fenpyroximate (z,e)
  7. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]

  8. Drug

    Bacteroides thetaiotaomicron

    go.drugbank.com/drugs/DB17879
    Investigational

    Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]

  9. Drug

    CYNK-101

    go.drugbank.com/drugs/DB18637
    Investigational

    CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).

    Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)
  10. Drug

    Famitinib

    go.drugbank.com/drugs/DB11741
    Investigational

    Famitinib has been used in trials studying the treatment of Colorectal Cancer, Renal Cell Cancer, Colorectal Cancer Recurrent, Colorectal Cancer Metastatic, and Metastatic Renal Cell Cancer, among others

    Categories: Receptor Protein-Tyrosine Kinases, antagonists & inhibitors